Breast cancer stands as the most commonly diagnosed malignant tumor among women worldwide. Every year, millions of women receive a breast cancer diagnosis, turning routine doctor’s visits into life-altering moments filled with fear, uncertainty, and questions about treatment, side effects, and long-term survival. Among all breast cancer subtypes, HER2-positive breast cancer represents about 15–20% of all early breast cancer cases, carrying unique biological traits that set it apart from hormone receptor-positive or triple-negative disease. For decades, doctors have relied on standardized chemotherapy plus HER2-targeted injections to shrink tumors before surgery—a process called neoadjuvant therapy—but this one-size-fits-all strategy carries heavy downsides: harsh chemotherapy side effects that drain patients’ energy, damage healthy organs, and sometimes deliver unnecessary intense treatment to women who might respond well to gentler regimens.
What if breast cancer treatment could stop being a rigid, identical formula for every patient? What if doctors could adjust therapy strength—dial back toxic drugs for fast responders, or ramp up targeted therapies for slow responders—based on real-time molecular and imaging data from each patient’s body? This is the core vision of a brand-new large-scale Chinese clinical trial, led by the National Cancer Center, Chinese Academy of Medical Sciences. This multicenter Phase III study aims to build a personalized, adaptive neoadjuvant treatment system for HER2-positive breast cancer, powered by multi-omics testing and real-time tumor response tracking. Instead of forcing every patient through the same harsh chemo cocktail, the trial creates a flexible treatment roadmap that scales therapy up or down according to each woman’s unique tumor signals. For ordinary patients and their families, this trial is more than just medical research: it represents a future where breast cancer care becomes kinder, more precise, and far more effective at saving lives without sacrificing quality of life.
What Is HER2-Positive Breast Cancer, and Why Standard Neoadjuvant Therapy Falls Short
To understand why this new adaptive treatment trial matters, we first break down the basics of HER2-positive breast cancer in simple, accessible language. Every breast cancer cell carries protein markers on its surface that shape how the tumor grows and responds to medicine. The HER2 protein is a growth switch: when cancer cells overproduce HER2 (the “HER2-positive” diagnosis), tumors multiply faster, spread more easily to nearby lymph nodes, and carry higher risk of recurrence if left untreated.
Two standard tests confirm HER2 status: IHC staining (a score of 3+ equals clear HER2 positivity) or ISH gene testing for ambiguous IHC 2+ results. For early or locally advanced HER2-positive breast cancer where the tumor measures over 2 centimeters and has spread to nearby lymph nodes (Stage II–IIIc), doctors routinely recommend neoadjuvant therapy: treatment delivered before surgical removal of the tumor. The primary goal of neoadjuvant care is pathological complete response, or pCR. Put simply, pCR means no living cancer cells remain in the breast or lymph nodes after preoperative therapy—this outcome strongly predicts long-term disease-free survival, making it the gold standard success marker for breast cancer treatment.
For years, the global standard neoadjuvant regimen for HER2-positive breast cancer is TCbHP: docetaxel (chemotherapy), carboplatin (chemotherapy), trastuzumab, and pertuzumab (two anti-HER2 antibody injections). This four-drug combination reliably boosts pCR rates, yet it comes with unavoidable drawbacks. Two strong chemotherapy agents mean high rates of severe fatigue, hair loss, low blood cell counts, nerve damage, kidney stress, and digestive distress. Many patients struggle to finish their full treatment course due to unmanageable toxicity, while others who have highly responsive tumors endure unnecessary heavy chemo when a lighter regimen would work equally well.
Medical researchers worldwide have spent years chasing de-escalated chemotherapy plans—cutting down harsh chemo drugs without losing anti-tumor power. A landmark Chinese Phase III study called HELEN-006 changed clinical guidelines by proving nab-PHP (albumin-bound paclitaxel plus dual anti-HER2 trastuzumab/pertuzumab) delivered higher pCR rates and far milder side effects than the standard TCbHP regimen. This breakthrough proved that lighter chemotherapy could outperform traditional heavy chemo for some HER2-positive patients, opening the door for personalized, reduced-toxicity neoadjuvant care.
At the same time, new anti-HER2 medications have exploded onto the cancer treatment scene, expanding our toolkit beyond trastuzumab and pertuzumab. Oral pyrotinib blocks HER2 from inside tumor cells; antibody-drug conjugates (ADCs) like T-DXd and SHR-A1811 carry chemo payloads directly into HER2 cancer cells for ultra-precise killing; everolimus suppresses a key cell growth pathway (PI3K/Akt/mTOR, shortened to PAM) that drives resistance to anti-HER2 drugs. Large global trials including PHEDRA, DESTINY-Breast 11, and a Phase II SHR-A1811 study confirmed these new agents deliver impressive pCR rates when used preoperatively, yet no unified strategy exists to match each drug to the right patient at the right time. Some patients respond instantly to mild nab-P+HP therapy; others carry PAM pathway mutations that render standard anti-HER2 drugs useless and require everolimus added to their regimen; slow responders need stronger ADC or anthracycline chemo combinations to hit pCR. Until now, doctors lacked a clear, validated system to sort patients into these tailored pathways mid-treatment.
This gap is exactly what sets out to fix. Unlike previous trials that test one single new drug against one standard regimen, this study builds a full adaptive decision tree guided by two real-time patient readouts: circulating tumor DNA (ctDNA) blood tests and radiology tumor scans after treatment cycles.
The Core Idea of This Adaptive Therapy Trial: Treat Each Patient’s Tumor, Not Just Her Diagnosis
Most clinical trials split patients into two fixed groups: either the standard treatment arm, or one single experimental drug arm, with no mid-treatment adjustments. This rigid design ignores a critical reality: tumors change as treatment progresses, and every patient’s cancer carries unique molecular fingerprints visible in their blood ctDNA. ctDNA are tiny fragments of cancer DNA shed into the bloodstream by active tumor cells. A negative ctDNA result after one cycle of therapy signals the tumor is already shrinking and responding well; a positive ctDNA reading means cancer cells remain active, and the starting regimen is not hitting the tumor hard enough. When paired with imaging scans that measure physical tumor shrinkage (partial response, or PR), ctDNA creates a two-part biomarker system to guide treatment upgrades or downgrades mid-neoadjuvant care.
The research team behind this trial built years of foundational data to support this adaptive framework. Previously, they assembled a nationwide multi-omics database covering 958 advanced breast cancer patients, integrating clinical medical records, tumor pathology slides, and serial ctDNA blood samples. This large dataset mapped common gene mutation patterns across all breast cancer subtypes and identified molecular markers that predict treatment failure or success. They further built a dynamic ctDNA monitoring library of 430 patients, tracking how cancer DNA shifts over months of chemotherapy and targeted therapy. By combining clinical, pathological, and genetic multi-omics data, the team mapped how tumors evolve under treatment pressure—laying solid groundwork to build a reliable response prediction model that powers this Phase III adaptive trial.
In simple terms, the study’s central hypothesis is straightforward: adjusting neoadjuvant therapy intensity based on early ctDNA and scan results will deliver equivalent or better pCR rates than static standard TCbHP treatment, while lowering overall chemotherapy toxicity for fast responders. Patients who show early tumor suppression can safely de-escalate to milder chemo-free or low-chemo regimens, while those with persistent cancer signals receive escalated targeted therapy to beat drug resistance.
Trial Basics: Who Can Join, Study Structure, and Two Treatment Arms
This is a nationwide, multicenter, prospective randomized controlled Phase III trial, planned to enroll 2,000 eligible women across Chinese cancer hospitals, split at a 1:3 ratio: 500 patients in the standard control group, 1,500 patients in the experimental adaptive therapy group. The trial will start estimated enrollment in November 2025, finish primary data collection by December 2027, and follow participants for up to three years to track long-term survival outcomes. Only women aged 18 to 70 qualify, with strict inclusion and exclusion rules designed to keep participants safe and create consistent, comparable research data.
Two Distinct Treatment Groups
Control Group: Fixed Standard TCbHP Regimen
The 500 control patients receive the global traditional neoadjuvant standard: docetaxel + carboplatin dual chemotherapy plus trastuzumab and pertuzumab dual anti-HER2 injections, with no mid-treatment dose or drug adjustments. Every patient follows the identical six-cycle schedule regardless of how their tumor responds, serving as the benchmark to measure the adaptive group’s performance.
Experimental Group: Dynamic De-Escalation/Escalation Adaptive Therapy
All 1,500 experimental patients start on the gentler nab-P+HP base regimen (albumin-bound paclitaxel low-dose chemo plus trastuzumab/pertuzumab dual HER2 blockade). After just one treatment cycle, doctors draw blood for ctDNA testing; after two full cycles, patients receive CT/MRI scans to measure tumor size and check for partial response (PR). From this two-part early data set, patients branch into four personalized treatment pathways:
- ctDNA negative + tumor achieves PR: Stay on the mild nab-P+HP regimen for all remaining cycles (de-escalation benefit: no carboplatin heavy chemo).
- ctDNA negative + no PR: Step up to two cycles of standard TCbHP to boost anti-tumor activity.
- ctDNA positive, no PAM pathway gene mutations: Switch to PyroHT (oral pyrotinib + trastuzumab + docetaxel) for two cycles to overcome slow response.
- ctDNA positive with PAM pathway mutations linked to drug resistance: Receive EveroHT (everolimus mTOR inhibitor + trastuzumab + docetaxel) for two cycles to block the resistance pathway.
After four total treatment cycles, patients undergo a second round of imaging scans. Those who now show partial response continue their assigned regimen for two more cycles before surgery. If tumors still fail to shrink after four cycles, doctors escalate further to powerful ADC targeted therapy or anthracycline-based AC+H chemo to maximize tumor shrinkage before surgery.
This branching design is the study’s revolutionary strength: no patient receives more intense treatment than their tumor biology demands, and no slow responder stays stuck on a weak, ineffective starting regimen.
What Outcomes Will Researchers Measure?
The trial tracks both short-term surgical success and long-term survival and quality-of-life metrics over two to three years of follow-up, split into primary and secondary endpoints for clear data analysis:
Primary Endpoint (Most Important Measurement)
Pathological complete response (pCR) rate at two years: the percentage of patients with zero invasive cancer cells left in breast and lymph nodes after neoadjuvant therapy and surgery. This single number will prove whether adaptive personalized treatment matches or outperforms the static standard TCbHP regimen.
Unlike older trials that only measure tumor shrinkage, this study centers patient experience as a core research goal, acknowledging that cancer treatment success means more than just eliminating cancer cells—it means preserving patients’ ability to work, care for family, and maintain mental wellbeing during therapy.
Why This Trial Changes the Future of HER2-Positive Breast Cancer Care
For decades, cancer treatment operated under a “one-size-fits-all” model dictated by tumor subtype and stage alone. This trial flips that script by building real-time molecular feedback into routine neoadjuvant care, delivering three transformative benefits for breast cancer patients:
- Reduced Unnecessary Chemotherapy Toxicity for Fast Responders
Thousands of HER2-positive patients each year endure carboplatin and high-dose taxane chemo despite their tumors responding rapidly to milder nab-P+HP dual anti-HER2 therapy. The adaptive framework lets these patients drop harsher chemo agents early, cutting down on hair loss, bone marrow suppression, nerve pain, and organ strain—an enormous quality-of-life win during the grueling preoperative treatment window. - Targeted Escalation for Slow Responders to Beat Drug Resistance
Many patients fail to reach pCR on standard regimens because hidden gene mutations (especially PAM pathway alterations) blunt anti-HER2 drug activity. Without ctDNA testing, doctors cannot identify these resistance drivers early and waste cycles on ineffective treatment before switching plans. This trial uses ctDNA to catch resistance signals after just one cycle, immediately adding pyrotinib or everolimus to counteract mutation-driven tumor growth, maximizing chances of shrinking tumors enough for curative surgery. For patients with persistent disease after four cycles, access to cutting-edge ADC therapy offers a stronger tumor-killing alternative unavailable in fixed standard regimens. - Builds a Replicable Multi-Omics Prediction Model for Global Clinical Use
Beyond comparing two treatment strategies, this trial includes translational research components designed to refine a multi-omics response prediction model combining ctDNA, imaging, and clinical pathology data. If validated, this model will become a low-cost, widely accessible tool for oncologists worldwide to personalize neoadjuvant therapy without requiring large clinical trial infrastructure. Low-resource cancer centers could adopt ctDNA testing to guide de-escalation/escalation decisions, democratizing personalized breast cancer care beyond top-tier urban hospitals.
This research also builds on China’s growing leadership in HER2-positive breast cancer innovation. Previous landmark Chinese trials (HELEN-006, PHEDRA) reshaped international treatment guidelines, and extends this legacy by creating the first large-scale Phase III adaptive neoadjuvant trial integrating ctDNA liquid biopsies into routine treatment decision-making. While major global trials like DESTINY-Breast 11 test single ADC agents against standard chemo, none have created a flexible, biomarker-guided treatment tree covering de-escalation and escalation pathways simultaneously.
Addressing Patient Concerns: Safety, Access, and Trial Limitations
For any patient considering joining a clinical trial, worries about safety, unknown side effects, and uncertain treatment outcomes are normal and valid. This trial includes strict safety guardrails to protect all participants:
- All patients receive standard-of-care anti-HER2 backbone therapy at minimum; no participant receives an inferior treatment with no active HER2 blockade.
- Organ function, heart health, and blood counts are monitored at every treatment cycle to pause or adjust therapy if toxicity emerges.
- Patients who fail to respond to four cycles of experimental therapy automatically escalate to powerful second-line targeted regimens, never stuck on ineffective mild treatment.
It is also important to clarify this study’s boundaries for readers: enrollment will only launch in November 2025, and final data readouts will not complete until late 2027, so results will not immediately change routine clinical practice today. The trial exclusively enrolls Chinese women at domestic multicenter cancer institutes, so international patients cannot participate directly. However, the translational research model generated from this work will be published in open-access medical journals, allowing global oncologists to adapt its biomarker framework for local patient populations.
Conclusion: A New Patient-Centered Vision for Breast Cancer Treatment
The Phase III adaptive neoadjuvant trial represents a paradigm shift in how we treat HER2-positive early breast cancer. For too long, women with identical HER2-positive diagnoses received identical heavy chemo regimens, regardless of their tumor’s unique molecular behavior and early treatment response. This research leverages years of Chinese multi-omics database work, groundbreaking domestic anti-HER2 drug trials, and minimally invasive ctDNA blood testing to build a flexible treatment system that meets each patient’s cancer exactly where it stands.
Fast responders gain relief from unnecessary toxic chemotherapy, while slow responders receive timely, targeted therapy upgrades to overcome drug resistance and boost odds of curative surgery. Beyond measuring pCR and survival statistics, the trial prioritizes patient quality of life, capturing how personalized treatment reduces the physical and emotional burden of breast cancer care. As enrollment opens across China’s major cancer centers starting November 2025, this landmark study will answer one of modern oncology’s most critical questions: can biomarker-guided adaptive therapy deliver safer, equally effective neoadjuvant care for HER2-positive breast cancer?
The results from this trial will not only update Chinese clinical practice guidelines but also provide a blueprint for global precision breast cancer research. For millions of women facing HER2-positive breast cancer worldwide, this adaptive treatment framework offers a hopeful future: one where cancer care stops treating the diagnosis, and starts treating the individual patient.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoRelated Clinical Trials
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
The purpose of this study to test an alternative treatment approach that involves giving participants radiotherapy before their mastectomy (preoperative radiotherapy) and performing immediate reconstruction surgery at the time of mastectomy. The immediate reconstruction surgery is called an immediate autologous reconstruction (IR) and is different than the standard reconstruction surgery people with T4 breast cancer have. IR is a surgical procedure where immediately following your mastectomy, the surgeon takes tissue from another part of your body and uses it to re-create your breast. The standard reconstruction surgery occurs later and can be done with an implant or tissue from your body. The main purpose of this study to find out if the alternative treatment approach shown above is feasible. The study will see how safe this alternative treatment approach is compared with the standard treatment approach.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoDose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
ICARUS-BREAST02 is an open-label, multicenter, phase 1b/2, platform study that aims to evaluate the safety, tolerability, and efficacy of HER3-DXd monotherapy and in combination with other anti-cancer agents in patients with ABC. The first 2 modules will evaluate: i. safety and efficacy of HER3-DXd with olaparib in patients with HER2-low and HER2-positive ABC progressed on T-DXd (Module 1) and HER3-DXd monotherapy in patients with HER2-low ABC progressed on T-DXd (Module 0). The main objective of Part 1 is to assess the safety and tolerability of HER3-DXd monotherapy and combination and to determine the recommended phase 2 dose (RP2D) of the combination containing HER3-DXd. The main objective of Part 2 is to assess the efficacy of study therapies in each module based on investigator assessment as evaluated by the objective response rate (ORR) at 6 months.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoBreast Cancer PSMA PET
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoShorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell’s deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body’s immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoMetabolic Flexibility and Autonomic Control After Muscle Power vs Metabolic Power Training in Postmenopausal Oncological Women: the POWER Health Study
POWER Health is a randomized clinical trial with a two-arm parallel design whose objectives are 1) to study metabolic flexibility and autonomic fuion (both capacities that describe cardiovascular health) in a sample of postmenopausal oncological women vs postmenopausal untreated controls (CT); and 2) to analyze the impact of two different 8-week physical exercise supervised interventions: HIIT training vs strength training focused on muscle power, on both cardiovascular capacities in these populations.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoEC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
compare the efficacy and safety of TCbHP and EC-THP regimen in HER2-positive breast cancer patients
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoProtective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfuion
Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac fuion. Recent advancements have increased cancer survivorship but it remains clinically challenging to mitigate the cardiotoxic side effects. Although there are several strategies used to reduce the occurrence and severity of DOX-induced cardiotoxicity, they are not particularly effective. Hence, there is an urgent need to develop new strategies that prevent the cardiotoxic effects of DOX but maintain its potency as a cancer therapy. Because the cellular events responsible for the antitumor activity of DOX and DOX-induced cardiotoxicity are distily different, it may be possible to develop therapies that selectively mitigate DOX-induced cardiotoxicity. Thus, the investigators propose to test an adjuvant therapy that combines the phytochemical sulforaphane (SFN) with DOX to attenuate DOX-induced cardiomyopathy. SFN activates the transcription factor Nrf2 and induces defense mechanisms in normal cells. Furthermore, SFN inhibits carcinogenesis and metastases and enhances cancer cell sensitivity to DOX, seemingly through Nrf2-independent mechanisms. SFN has also been tested in several clinical trials, although never together with DOX. Our early animal studies suggest that by activating Nrf2, SFN selectively protects the mouse and rat from DOX cardiotoxicity, enhances survival and enhances the effects of DOX on cancer growth in a rat breast cancer model. The investigators suspect that SFN affects DOX metabolism in cancer cells to enhance tumor regression, or it may synergistically activate other key antitumor mechanisms. Hence, SFN may improve the clinical outcome of cancer therapy by (1) attenuating DOX cardiotoxicity and (2) enhancing the effects of cancer treatment on the tumor. Our hypothesis is that SFN protects the heart from DOX-mediated cardiac injury without altering the antitumor efficacy of DOX. In Aim 1, the investigators will conduct an early-phase clinical trial to determine if SFN is safe to administer to breast cancer patients undergoing DOX chemotherapy. In Aim 2, the investigators will determine if SFN decreases DOX-induced inflammatory responses and enhances Nrf2- and SIRT1-target gene expression in breast cancer patients. Notably, transcript and protein signatures in peripheral blood mononuclear cells (PBMCs) can predict cardiac fuion in patients undergoing DOX chemotherapy for breast cancer. The investigators will also determine if SFN/DOX treatment activates Nrf2- and SIRT1-dependent gene expression, alters the levels of biomarkers for presymptomatic DOX-cardiotoxicity and mitigates the generation of cardiotoxic metabolites in PBMCs and plasma. These studies will facilitate the development of SFN co-treatment as a strategy to enhance the efficacy and safety of DOX cancer therapy.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoClinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairment in Breast and Gynecological Cancer Patients
The purpose of this study is to assess the feasibility of a wearing semiconductor embedded headband for cancer-related cognitive impairment in patients with breast or gynecological cancers. The study will also test the safety and effectiveness of using a semiconductor embedded headband by using a cross-over study design. The study will consist of the following phases: * Phase 1: Participants will be randomly assigned to either receive a headband with an active semiconductor or they will receive a sham headband with no semiconductor. They will wear the assigned headband for 18 hours a day for 3 weeks. * Washout Period: After the first 3-week phase, there will be a 2-week “washout” period. During this time, participants will not wear either headband to allow time for the potential treatment effects to clear from their body. * Phase 2: After the washout period, participants will switch to the other headband they were previously not receiving. They will wear this assigned headband for 18 hours a day for 3 weeks.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoComparison of IPC Therapy as an Alternative or an Adju to MLD Within CDT for BCRL
Breast cancer is the most common cancer among women worldwide and lymphedema is one of its most significant complications. Breast cancer-related lymphedema (BCRL) may develop shortly after treatment or even years later, causing physical and psychological burden, fuional impairment, and reduced quality of life. Complete decongestive therapy (CDT), which includes manual lymph drainage (MLD), compression, skin care, and exercise, is the standard approach. Intermittent pneumatic compression (IPC) has been proposed as an additional option, and current consensus reports emphasize the need for studies evaluating IPC in combination with MLD. Previous studies comparing IPC and MLD, either alone or in combination, have shown inconsistent results. Some reported no significant difference between treatment groups, while others suggested additional benefits of IPC, particularly in reducing limb heaviness and tension. However, there is still insufficient evidence to clarify the exact role of IPC within CDT. The aim of this study is to investigate the acute effects of using IPC instead of MLD, or in combination with MLD, on arm circumference, arm volume, shoulder range of motion, and quality of life in patients with BCRL.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cyclin-dependent kinase inhibitor (CDKi) setting.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Study of HLD-0117 in Patients With Metastatic Breast Cancer
Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoTCb vs EC-T in High Risk ER+/HER2- Breast Cancer
This study will evaluate the efficacy and safety of docetaxel plus carboplatin (TCb) regimen compared with conventional chemotherapy regimen (epirubicin plus cyclophosphamide followed by docetaxel, EC-T) regimen as adjuvant chemotherapy in patients with early-stage high-risk estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoTime Restricted Eating During Chemotherapy for Breast Cancer
Breast cancer is the most common cancer in the United States however, little is known about how diet can affect cancer treatment. Pre-clinical murine studies report intermittent fasting increases effectiveness of chemotherapy and decreases treatment related adverse events. The proposed research will demonstrate that time restricted eating, a form of intermittent fasting, will improve treatment related outcomes, patient related outcomes, and limit treatment related weight gain and fat mass accretion.Time restricted eating combined with a mediterranean diet will also be feasible and improve cardiometabolic risk more than TRE alone or standard care.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoRaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer
This study is an open-label, controlled, multicenter phase III clinical trial designed to evaluate whether the use of iodine-125 radioactive seed markers can improve treatment response for patients with early or locally advanced breast cancer undergoing neoadjuvant therapy. Neoadjuvant therapy is widely used for breast cancer to shrink tumors, increase the chances of breast-conserving surgery, and help determine the most effective postoperative treatments. Achieving a pathological complete response (pCR) after neoadjuvant therapy is strongly associated with better long-term outcomes. In this study, qualified participants will be randomly assigned in a 1:1 ratio to either the experimental group or the control group. Experimental group: Patients will receive placement of iodine-125 seed markers in the primary breast tumor and biopsy-proven positive axillary lymph nodes before starting neoadjuvant therapy. Control group: Patients will undergo standard neoadjuvant therapy without seed placement. All participants will then complete neoadjuvant therapy followed by surgery. Pathological evaluation will determine whether the cancer has completely disappeared. Long-term outcomes, including invasive disease-free survival, will be followed for at least five years. The goal of this study is to determine whether radioactive seed marking can increase the rate of pathological complete response and improve prognosis in patients receiving neoadjuvant therapy for breast cancer. The study will also explore whether iodine-125 seeds may activate immune responses that contribute to treatment effectiveness.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoUltra-hypofractionated for Whole Breast Irradiation (WBI) Compared to Partial Breast Irradiation (PBI)
Female patients undergoing surgical treatment for early breast cancer and meeting the inclusion criteria for adjuvant breast radiotherapy were randomized into two groups. One group will receive adjuvant whole-breast radiotherapy in ultra-hypofractionated regimen of 26 Gy in 5 fractions. In contrast, the other group will receive partial breast irradiation with a dose of 26Gy in 5 fractions. The study’s objective is to compare the effects of both breast radiotherapy protocols in terms of locoregional disease control and survival and to compare the adverse effects of radiotherapy between the two protocols. To determine if there is a correlation between different parameters and the efficacy and degree of toxicity for both protocols.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoNeoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
This is a Phase II trial to assess efficacy and feasibility of pembrolizumab + INBRX-106 as an induction therapy preceding neoadjuvant therapy.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoAdebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
This is an open-label, single-arm, exploratory study planned to include 40 patients with HRD-positive HR +/HER2- advanced breast cancer treated with Adebrelimab in combination with fluzoparib. To observe and evaluate the efficacy and safety of Adebrelimab combined with fluzoparib in the treatment of HRD-positive HR +/HER2-advanced breast cancer
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude)
The goal of this study is to determine if the intervention or if general information about being a breast cancer survivor can help Breast Cancer Survivors reduce their fear of recurrence. The main question it aims to answer are: Can the FoRtitude intervention lower the fear of recurrence for Breast Cancer Survivors? Participants will: Answer questions about their fear of recurrence. Be randomized to 1 of the 3 following options: (1) a weblink to access an eHealth intervention which includes a website and an optional interactive text-messaging feature, (2) a weblink to a non-interactive website that will include links to external websites with general information that may be helpful for Breast Cancer Survivors, or (3) you will need to talk with your oncology team about your concerns about recurrence or seek psychosocial care in the community. Be asked to fill out questionnaires 5 times for up to 18 months.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoEffects of Neoadjuvant Prehabilitation on Post-Interventional Physical and Psychological Outcomes in Oncology Patients With Solid Tumors
The goal of NEOPRO-SIT is to establish and evaluate a neoadjuvant prehabilitation program comprised of targeted exercise therapy and structured psycho-oncological support in patients with solid tumors. The main question is: Will targeted exercise therapy and structured psycho-oncological support increase both physical and psychological capacity as well of quality of life compared to standard of care in a prehabilitation setting? Researchers will: compare a prehabilitation program to standard of care Participants will: receive either standard or care or a comprehensive prehabilitation program
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoLuminal Breast Cancer Cryoablation
LUBRECA will evaluate the safety and efficacy of cryoablation with liquid nitrogen to treat cT1cN0 luminal breast cancer diagnosed in postmenopausal women
PDF$29 only! Buy Clinical Trial Full Report With Contact Info